Listing 1 - 10 of 17 | << page >> |
Sort by
|
Choose an application
The Internet offers consumers a convenient method for purchasing drugs that is sometimes cheaper than buying from traditional brick-and-mortar pharmacies. According to a recent FDA survey, nearly 1 in 4 adult U.S. Internet consumers have purchased prescription drugs online. However, many Internet pharmacies are fraudulent enterprises that offer prescription drugs without a prescription and are not appropriately licensed. These rogue Internet pharmacies may sell drugs that are expired, improperly labeled, or are counterfeits of other drugs. A number of federal and state agencies share responsib
Internet pharmacies --- Electronic commerce --- Cybercommerce --- E-business --- E-commerce --- E-tailing --- eBusiness --- eCommerce --- Electronic business --- Internet commerce --- Internet retailing --- Online commerce --- Web retailing --- Commerce --- Information superhighway --- Internet drugstores --- Web drugstores --- Web pharmacies --- Drugstores --- Safety measures --- E-books --- Internet pharmacies. --- Security measures. --- Security measures
Choose an application
Internet pharmacies --- Drugs --- Hospitals --- Benevolent institutions --- Infirmaries --- Health facilities --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Pharmacology --- Pharmacy --- Internet drugstores --- Web drugstores --- Web pharmacies --- Drugstores --- Electronic commerce --- Prescribing --- Data processing. --- Drug distribution systems --- Prescribing&delete& --- Data processing --- E-books
Choose an application
Written by internationally acclaimed experts in the economics of innovation, this volume examines how the biotechnology and pharmaceutical sector is affected by the dynamics of innovation, institutions, and public policy. It contributes both theoretically and empirically to the increasingly influential Schumpetarian framework in industrial economics, which places innovation at the centre of the analysis of competition. Both quantitative and qualitative studies are included, and this varied perspective adds to the richness of the volume's insights. The contributors explore different ideas regarding the historical evolution of technology in the sector, and how firms and industry structure have co-evolved with innovation dynamics. Important policy questions are considered regarding the future of innovation in this sector and its impact on the economy.
Drug Industry --- Biomedical Research --- Biomedical Technology --- Economics, Pharmaceutical --- Technology, Pharmaceutical --- Pharmaceutical biotechnology --- Research, Industrial --- Industrial organization (Economic theory) --- Technological innovations --- 338.730 --- 338.754.12 --- AA / International- internationaal --- 615.12 --- 615.12 Pharmaceutical laboratories and pharmacies --- Pharmaceutical laboratories and pharmacies --- Breakthroughs, Technological --- Innovations, Industrial --- Innovations, Technological --- Technical innovations --- Technological breakthroughs --- Technological change --- Creative ability in technology --- Inventions --- Domestication of technology --- Innovation relay centers --- Technology transfer --- Contract research --- Industrial research --- Research --- Engineering experiment stations --- Biopharmaceutical technology --- Drugs --- Biotechnology --- Pharmaceutical technology --- Industrial economics --- Market structure --- Microeconomics --- Extractieve nijverheid: algemeenheden --- Farmaceutische producten en parfumerie --- Business, Economy and Management --- Economics --- Pharmaceutical biotechnology. --- Research, Industrial. --- Technological innovations. --- Acqui 2006
Choose an application
Biotechnology industries. --- Pharmaceutical industry. --- Biotechnology. --- Biodiversity conservation --- Bio-industries --- Industrie pharmaceutique --- Biotechnologie --- Biodiversité --- Conservation --- 615.12 <1-775> --- 615.12 <1-773> --- Biological diversity conservation --- Biotechnology --- Biotechnology industries --- Pharmaceutical industry --- AA / International- internationaal --- 338.754.10 --- 338.754.4 --- 351.2 --- 338.043 --- 338.724 --- 338.6 --- biochemie --- biotechnologie --- handel, internationaal --- milieuproblematiek --- ontwikkelingslanden --- pharmacie --- scheikundige industrie --- Drug industry --- Drug trade --- Chemical industry --- High technology industries --- Chemical engineering --- Genetic engineering --- Biodiversity --- Conservation of biodiversity --- Diversity conservation, Biological --- Gender mainstreaming in biodiversity conservation --- Maintenance of biological diversity --- Preservation of biological diversity --- Conservation of natural resources --- Ecosystem management --- Pharmaceutical laboratories and pharmacies--Ontwikkelde gebieden --- Pharmaceutical laboratories and pharmacies--Gebieden in ontwikkeling. Ontwikkelingslanden --- Industrie van de eigenlijke chemische producten (algemeen). --- Levensmiddelenindustrie. --- Openbare gezondheid. Milieubescherming. Milieuvervuiling. --- Technologische vooruitgang. Automatisering. Computers. Werkgelegenheid en informatica. --- Teelten. --- Wetenschappelijk onderzoek en ontwikkeling. --- 615.12 <1-773> Pharmaceutical laboratories and pharmacies--Gebieden in ontwikkeling. Ontwikkelingslanden --- 615.12 <1-775> Pharmaceutical laboratories and pharmacies--Ontwikkelde gebieden --- Biodiversité --- Medicine industry --- Medicines industry --- Prescription medicine industry --- Technologische vooruitgang. Automatisering. Computers. Werkgelegenheid en informatica --- Wetenschappelijk onderzoek en ontwikkeling --- Teelten --- Industrie van de eigenlijke chemische producten (algemeen) --- Levensmiddelenindustrie --- Openbare gezondheid. Milieubescherming. Milieuvervuiling --- Biomedical industries
Choose an application
Out-of-pocket payments (OOPs) are direct (at the point of service) financial contributions or co-payments by patients and their families associated with consumption of medical products (such as medicines) and/or services. They can be formal as well as informal payments. Together with taxation, social and private health insurance contributions, they constitute the main sources of financing for medical products and services in all countries of the world. This policy note looks at prevalence and trends of OOPs in Moldova during 2007-2013, evaluates their impact on the population's economic well-being (section two), identifies key drivers of the current OOPs (section three), and, based on the analysis, suggests several policy options for government's consideration (section four).
Access to Health Services --- Children --- Communicable Diseases --- Doctors --- Employment --- Equity --- Expenditures --- Health --- Health Economics & Finance --- Health Insurance --- Health Outcomes --- Health Policy --- Health System Performance --- Health Systems Development & Reform --- Health, Nutrition and Population --- Hospitals --- Human Development --- Insurance --- International Comparisons --- Internet --- Living Standards --- Migration --- Nurses --- Pharmacies --- Population --- Poverty --- Price Elasticity --- Private Health Insurance --- Private Sector --- Public Health --- Quality Control --- Social Health Insurance --- Social Insurance --- Unemployment --- Workers
Choose an application
This report analyses equity and financial protection in the health sector of Timor-Leste. In particular, it examines inequalities in health outcomes, health behavior and health care utilization; benefit incidence analysis; financial protection; and the progressivity of health care financing. Data are drawn from the 2009-2010 Demographic and Health Survey, the 2001-2002 and 2007-2008 Living Standards and Measurement Surveys as well as 2011-2012 Household Income Expenditure Survey, and the Ministry of Finance. All analyses are conducted using original data and performed using the health modules of the ADePT software.
Child Health --- Children --- Disease Control & Prevention --- Doctors --- Equity --- Expenditures --- Financial Management --- Gender --- Health --- Health Economics & Finance --- Health Finance --- Health Insurance --- Health Monitoring & Evaluation --- Health Outcomes --- Health Professionals --- Health System Performance --- Health Systems Development & Reform --- Health, Nutrition and Population --- Hospitals --- Household Income --- Human Development --- Human Resources --- Infant Mortality --- Insurance --- Living Standards --- Measurement --- Mortality --- Nurses --- Nutrition --- Obesity --- Pharmacies --- Polio --- Population --- Poverty --- Private Sector --- Public Health --- Public Hospitals --- Public Spending --- Rehabilitation --- Risk --- Sexually Transmitted Diseases --- Social Insurance --- Weight --- Workers
Choose an application
Nicaragua, a largely urban country (56 percent of the population lives in urban areas), is one of the least populous (5.53 million) and poorest countries in CentralAmerica. Following reforms in the 1980s, Nicaragua made remarkable progress in gender equity in education and the labor force, while the wide availability of primary health care initiated in the 1970's, including family planning services, led to improvements in infant and child mortality rates. Several lessons emerge from Nicaragua's success at reducing fertility. The government was committed to gender equity and female empowerment through educating girls and women and recruiting women into the labor force. Family planning services were provided within a well functioning primary health care system, including an extensive, efficient contraceptive distribution network that works with international donors, and international and national Non-Governmental Organizations (NGOs) to offer women a good mix of options. Demand must be created through a timely public education campaign. Success requires civic engagement with stakeholders, which may initially mean avoiding unnecessary confrontation and publicity of services for addressing the concerns of more conservative stakeholders.
Abortion --- Access to Education --- Access to Health Services --- Adolescent Health --- Adolescents --- Birth Control --- Cash Crops --- Child Health --- Child Mortality --- Civil Society Organizations --- Demographics --- Disasters --- Domestic Violence --- Drugs --- Educational Attainment --- Family Planning --- Fertility --- Gender --- Gross National Income --- Health Education --- Health Monitoring & Evaluation --- Health, Nutrition and Population --- Immunizations --- Infant Mortality --- Labor Market --- Life Expectancy --- Market Economy --- Measles --- Natural Disasters --- Nurses --- Nutrition --- Pharmacies --- Pregnancy --- Primary Education --- Public Health --- Quality of Life --- Reproductive Health --- Secondary Education --- Sex Education --- Unions --- Urban Areas --- World Health Organization
Choose an application
Botswana has had a stable democratic government and good governance since independence in 1966. With a sustained high average economic growth (about 9 percent) fueled by the diamond mining industry, it is the only country in Africa listed among the 13 'economic miracles' of the world for 1960-2005. The total fertility rate remains high in Sub-Saharan Africa, with 25 countries showing a rate greater than 5.0. In contrast, Botswana experienced the greatest fertility decline in the region during 1980-2006, with the total fertility rate decreasing from 7.1 in 1981 to 3.2 in 2006. The Botswana national family planning program, judged the strongest in Africa, contributed to this decline. The government strongly committed to meeting family planning needs, integrated maternal and child health/family planning (MCH/FP) and sexually transmitted infection (STI) services in 1973. The government spends about 18 percent of its total budget on health, a higher proportion than the Abuja declaration's target of 15 percent.
Abortion --- Adolescent Health --- Adolescents --- Breastfeeding --- Cervical Cancer --- Child Development --- Child Health --- Demographics --- Dependency Ratio --- Drugs --- Epidemiology --- Family Health --- Family Planning --- Gender --- Good Governance --- Health Education --- Health Monitoring & Evaluation --- Health Systems Development & Reform --- Health, Nutrition and Population --- Hospitals --- Household Surveys --- Infant Mortality --- Intrauterine Devices --- Life Expectancy --- Maternal Mortality --- Mental Health --- Migration --- Mortality --- Nutrition --- Oral Contraceptives --- Pharmacies --- Physicians --- Population Growth --- Posters --- Postnatal Care --- Pregnancy --- Public Health --- Public Hospitals --- Reproductive Health --- Secondary Education --- Sterilization --- Tuberculosis --- Unions --- Urban Areas --- Urban Population --- Urbanization --- World Health Organization
Choose an application
The Kamagayan Comprehensive Care Center (KC3) clients report being very satisfied with the comprehensive package of health services offered under the BCP and they feel welcome and accepted at the KC3. Community members in Kamagayan, including family members of the KC3 clients, also praise the service as an excellent intervention. Virtually all key stakeholders interviewed noted that the KC3 team had performed especially well in building trust between clients and their health service providers, families, and community. In that sense, community-based advocacy efforts were successful at generating an enabling environment for service delivery. The KC3 clients, family members, and community representatives also appreciated efforts from the KC3 team to promote demand reduction through counseling, Narcotics Anonymous (NA) sessions, and privileged access to the Argao Treatment and Rehabilitation Center (TRC). There is great demand and genuine interest among the KC3 clients and patients' clients to become peer educators and provide support to PWID. The professionalization of PWID through peer educator roles has also reportedly reduced stigma and discrimination and increased acceptance of PWID in the community. Should services for PWID be scaled up in Cebu and beyond, recruiting a workforce of peer educators should not be a critical challenge, an important lesson learned for future harm reduction projects in the Philippines.
Adolescent Health --- Aids --- Alcoholism --- Amphetamines --- Capacity Building --- Children --- Civil Society Organizations --- Communication Channels --- Crime --- Discrimination --- Drugs --- Epidemiology --- Good Governance --- Health --- Health Monitoring & Evaluation --- Health System Performance --- Health, Nutrition and Population --- Hiv/Aids --- Human Development --- Human Rights --- Hygiene --- Informed Consent --- Injecting Drug Users --- Malaria --- Marketing --- Needs Assessment --- Peer Groups --- Pharmacies --- Posters --- Prevention --- Prostitution --- Public Health --- Respect --- Sex Workers --- Sterilization --- Substance Abuse --- Technical Assistance --- Tuberculosis --- Women --- Workers --- World Health Organization
Choose an application
Pharmaceuticals are essential to achieve health outcomes, but are at the same time a major cost factor in every health system. From a patient perspective, access to pharmaceuticals is a proxy for the functioning of the health system. With increasing economic strength, patients become more demanding with regard to access to modern, sophisticated drugs and providers become more aggressive in marketing those drugs. This paper reflects the situation in the pharmaceutical sector in Turkey, identifies critical issues, and discusses policy options based on current trends and the overall policy objectives of the Turkish government. This paper is structured as follows: chapter one gives introduction; chapter two gives overall policy objectives in the pharmaceutical sector in Turkey; chapter three presents institutional and regulatory framework; chapter four presents reimbursement rules; chapter five focuses on governance issues in the pharmaceutical sector; chapter six gives market overview; chapter seven gives payment for pharmaceuticals in Turkey; chapter eight presents prescribing practices - rational use of medicines; and chapter nine gives conclusions and way forward.
Antibiotics --- Bribery --- Burden of Disease --- Clinical Trials --- Consumer Protection --- Corruption --- Counterfeit Drugs --- Crime --- Decision Making --- Doctors --- Employment --- Expenditures --- Fraud --- Generic Drugs --- Gross Domestic Product --- Health Insurance --- Health Law --- Health Monitoring & Evaluation --- Health Outcomes --- Health Policy --- Health Systems Development & Reform --- Health, Nutrition and Population --- Heroin --- Hospitals --- Law and Development --- Leukemia --- Marketing --- Nurses --- Nutrition --- Patents --- Pharmaceutical Industry --- Pharmaceuticals --- Pharmaceuticals & Pharmacoeconomics --- Pharmacies --- Physicians --- Private Health Insurance --- Public Health --- Public Hospitals --- Surgery --- Workers
Listing 1 - 10 of 17 | << page >> |
Sort by
|